Cargando…
Surfactant protein D: A useful biomarker for distinguishing COVID‐19 pneumonia from COVID‐19 pneumonia‐like diseases
INTRODUCTION: Computed tomography is useful for the diagnosis of coronavirus disease (COVID‐19) pneumonia. However, many types of interstitial lung diseases and even bacterial pneumonia can show abnormal chest shadows that are indistinguishable from those observed in COVID‐19 pneumonia. Thus, it is...
Autores principales: | Togashi, Yuki, Kono, Yuta, Okuma, Takashi, Shioiri, Nao, Mizushima, Reimi, Tanaka, Akane, Ishiwari, Mayuko, Toriyama, Kazutoshi, Kikuchi, Ryota, Takoi, Hiroyuki, Abe, Shinji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059194/ https://www.ncbi.nlm.nih.gov/pubmed/35509408 http://dx.doi.org/10.1002/hsr2.622 |
Ejemplares similares
-
Double‐ring sign in granulocyte colony‐stimulating factor‐induced vasculitis
por: Mizushima, Reimi, et al.
Publicado: (2022) -
Early intervention of plasma exchange combined with intensive immunosuppressive treatment for anti-MDA-5 antibody–positive rapidly progressive interstitial pneumonia: Two case reports
por: Ishiwari, Mayuko, et al.
Publicado: (2021) -
Impact of sarcopenia on chemotherapy‐triggered exacerbation of interstitial lung disease in patients with non‐small cell lung cancer
por: Kikuchi, Ryota, et al.
Publicado: (2021) -
Polymyxin B haemoperfusion treatment for respiratory failure and hyperferritinaemia due to COVID‐19
por: Ishiwari, Mayuko, et al.
Publicado: (2020) -
Glasgow Prognostic Score predicts chemotherapy‐triggered acute exacerbation‐interstitial lung disease in patients with non‐small cell lung cancer
por: Kikuchi, Ryota, et al.
Publicado: (2021)